2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Antibodies with improved potency and breadth: Reduction in VL after VRC01LS or VRC07-523LS Infusion
6
6
Subject1
Subject8 Subject9 Subject10 Subject11 Subject12 Subject13 Subject14 Subject15 Subject16
Subject2 Subject3
5
5
Subject4
4
4
Subject5 Subject6
2 log 10 virus load 3
2 log 10 virus load 3
Subject7
(copies/ml)
(copies/ml)
LOD
LOD
1
1
0
2
4
6
8
10 12 14
0
2
4
6
8
10 12 14
Dayspost infusion
Dayspost infusion
VRC01LS
VRC07-523LS
- Day 7:2/7decrease of at least 0.9 log10 - Day 14:2/7decrease of at least 1.6 log10 (all subjects off ARVs)
- Day 7:8/9decrease of at least 1.2 log10;2/9 decrease of least 2 log10 - Day 14:6/9decrease of at least 1.6 log10;7/9 decrease of at least 0.6 log10 (all subjects off ARVsuntil after Day 14)
Study ofLAcabotegravir+ VRC07- 523LSbeing launched (ACTG)
ChenG IAS2019WEAA0305LB
Slide40of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS USA.
Selected other investigational drugs in the pipeline
http://i-base.info/htb/wp-content/uploads/2019/07/PIPELINE-2019-FINAL-full-version.pdf
Slide41of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS USA.
New Delivery Systems (in development)
Long acting injectables: o Elsulfavirine (NNRTI); raltegravir; atazanavir/ritonavir; combinectin (entry inhibitor) o Considerations: managing toxicities if they develop; what to do if recipients become pregnant; what happens if doses missed Implants: o Islatravir: NRTTI o TAF: NRTI o Biodegradable, removable, polymer-based implants with multiple drugs Patches Oral once-weekly delivery system Novel antibody delivery systems: viral vectors; synthetic DNA GulickR&Flexner C.AnnRevMed2019;70:137-50;FlexnerC.CurrOpinHIVAIDS2018;BenhabbourSRetal,NatureComm2019;Rajolietal. Eur Jof PharmaandBiopharm2019.GiardielloM NatureComm2016;KirtaneA,etal. NatureComm2018.WiseMetal, JCI,2019
Slide42of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS USA.
Made with FlippingBook flipbook maker